Haemonetics (HAE) Tops Q3 EPS by 18c, Revenues Beat; Raises FY20 EPS Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $118.51 +2.02%
Revenue Growth %: +5.6%
Financial Fact:
Operating income: 24.79M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +5.6%
Financial Fact:
Operating income: 24.79M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q3 EPS of $0.94, $0.18 better than the analyst estimate of $0.76. Revenue for the quarter came in at $259 million versus the consensus estimate of $255.4 million.
GUIDANCE:
Haemonetics sees FY2020 EPS of $3.30-$3.40, versus the consensus of $3.18.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Accenture shares fall on insider sales and analyst downgrade
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Corporate News, Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
